Pausing arthritis drug may boost pneumonia Shot's power

NCT ID NCT07242092

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study tests whether temporarily stopping methotrexate for 2 weeks after receiving a pneumonia vaccine (PCV20) helps the vaccine work better in adults with autoimmune rheumatic diseases like rheumatoid arthritis or lupus. About 192 participants with stable, low disease activity will be randomly assigned to either pause methotrexate or continue it as usual. The main goal is to see if more people develop protective antibodies after vaccination.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
20-valent pneumococcal conjugate vaccine (PCV20)
What this could lead to
If it works, this could show that a short break from methotrexate helps the pneumonia vaccine work better in people with rheumatic diseases, potentially improving protection against serious infections.
What could go wrong
This is a small, early-phase trial (192 people) looking at immune markers, not actual infection rates. Pausing methotrexate may cause disease flares in some participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE RHEUMATIC DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Reumatology division of Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo

    RECRUITING

    São Paulo, São Paulo, 05403-000, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.